TY - JOUR
T1 - Solitary Leptomeningeal Recurrence From Prostate Adenocarcinoma After Treatment With Cytotoxic Gene Therapy, Radiation Therapy, and Androgen Deprivation Therapy
AU - Chevli, Neil
AU - Curtis, Amarinthia E.
AU - Powell, Suzanne
AU - New, Pamela
AU - Butler, E. Brian
AU - Teh, Bin S.
N1 - Funding Information:
Sources of support: This work had no specific funding.
Publisher Copyright:
© 2021 The Author(s)
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Purpose: Leptomeningeal disease in prostate adenocarcinoma is very rare. Solitary leptomeningeal recurrence from prostate adenocarcinoma has only been previously reported once in the published literature. Methods and Materials: A 63-year-old man with high-risk prostate cancer was treated in a phase I-II trial with androgen deprivation, radiation therapy, and cytotoxic gene therapy. He initially had biochemical control but experienced solitary leptomeningeal recurrence 47 months after diagnosis. Results: He received androgen deprivation, radiation therapy to the lumbar and sacral spine, and stereotactic radiosurgery to 3 intracranial foci of disease. He died 14 months after leptomeningeal recurrence. Autopsy showed diffuse spinal leptomeningeal disease, leptomeningeal based intracranial lesions, and no other metastasis. Conclusions: The cause for solitary leptomeningeal recurrence in this patient is unknown. Although there may be many possible mechanisms, we speculate that it could be related to his initial treatment with cytotoxic gene therapy along with radiation therapy and androgen deprivation.
AB - Purpose: Leptomeningeal disease in prostate adenocarcinoma is very rare. Solitary leptomeningeal recurrence from prostate adenocarcinoma has only been previously reported once in the published literature. Methods and Materials: A 63-year-old man with high-risk prostate cancer was treated in a phase I-II trial with androgen deprivation, radiation therapy, and cytotoxic gene therapy. He initially had biochemical control but experienced solitary leptomeningeal recurrence 47 months after diagnosis. Results: He received androgen deprivation, radiation therapy to the lumbar and sacral spine, and stereotactic radiosurgery to 3 intracranial foci of disease. He died 14 months after leptomeningeal recurrence. Autopsy showed diffuse spinal leptomeningeal disease, leptomeningeal based intracranial lesions, and no other metastasis. Conclusions: The cause for solitary leptomeningeal recurrence in this patient is unknown. Although there may be many possible mechanisms, we speculate that it could be related to his initial treatment with cytotoxic gene therapy along with radiation therapy and androgen deprivation.
UR - http://www.scopus.com/inward/record.url?scp=85108249516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108249516&partnerID=8YFLogxK
U2 - 10.1016/j.adro.2021.100711
DO - 10.1016/j.adro.2021.100711
M3 - Article
AN - SCOPUS:85108249516
SN - 2452-1094
VL - 6
JO - Advances in Radiation Oncology
JF - Advances in Radiation Oncology
IS - 4
M1 - 100711
ER -